IMMUNOFUTURE
ImmunoFuture develops and researches drug discovery in infectious diseases and develops pharmaceuticals and treatment methods. The company was founded in 2007 and is based in Tokyo, Japan.
IMMUNOFUTURE
Industry:
Biopharma Medical Pharmaceutical
Founded:
2007-03-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Status:
Active
Similar Organizations
Huvet Bio
Huvet Bio is engaged in the research and development of bio pharmaceuticals.
Current Employees Featured
More informations about "ImmunoFuture"
ImmunoFuture - Contacts, Employees, Board Members, Advisors …
ImmunoFuture develops and researches drug discovery in infectious diseases and develops pharmaceuticals and treatment methods.See details»
ImmunoFuture - Crunchbase
ImmunoFuture develops and researches drug discovery in infectious diseases and develops pharmaceuticals and treatment methods.See details»
Home Page - Canada’s Immunoengineering and Biomanufacturing …
Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH) is bringing together a coalition of partners to accelerate the development and manufacturing of lifesaving medicines …See details»
ImmunoFuture, Inc. - Products, Competitors, Financials, Employees ...
About ImmunoFuture, Inc. Provider of medical research-related services. The company engages in incubation and comercialisation of projects selected from medical research results. The …See details»
AVENGER - Canada’s Immunoengineering and Biomanufacturing …
Advanced LNP RNA Vaccines Engineered with Next-Generation designs to Enhance pandemic Readiness. Dr. Anna Blakney and her team in the lab. AVENGER will establish a national …See details»
About Canada’s Immuno-Engineering and Biomanufacturing Hub
Mar 15, 2023 Canada’s Immuno-Engineering and Biomanufacturing Hub brings together a multi-disciplinary, multisectoral coalition of more than 50 partner institutions (9 academic, 15 private, …See details»
The future of immuno-oncology research: Challenges, innovations, …
This white paper offers an in-depth look at immuno-oncology (IO) research, emphasizing how data-driven research propels therapy development and enhances treatment efficacy. Download for a comprehensive analysis of the IO landscape, its projected market growth, and insights regarding pharmaceutical companies' strategic approaches to optimize therapeutic outcomes.See details»
The Comprehensive Analysis for the Transcriptional Organization …
The objective of this study is to investigate the transcriptional organization of stimuli responses and to clarify a character of RA-FLS. Methods: Synovium were obtained from RA (n = 21) and …See details»
Future potential of vaccines
260. There are 260 new vaccines being developed to protect against a number of diseases and pathogens which lack effective vaccines [2].See details»
Immunotherapy Drug Development Pipeline Shifts from …
Apr 18, 2023 The Cancer Research Institute (CRI), established in 1953, is a top-rated U.S. nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and …See details»
ImmunoFuture - Tech Stack, Apps, Patents & Trademarks
ImmunoFuture develops and researches drug discovery in infectious diseases and develops pharmaceuticals and treatment methods.See details»
Home - SITC 2025
Make your mark at the largest cancer immunotherapy conference and exhibit at SITC’s 40 th Anniversary Annual Meeting, hosted by the leading member-driven organization focused on …See details»
The immuno-oncology framework: Enabling a new era of cancer …
CIC-CRI and another partner organization, the international Society for Biological Therapy of Cancer (iSBTc; now the Society for Immunotherapy of Cancer) formed a community-wide …See details»
Human immunology and immunotherapy: main achievements and …
Sep 2, 2020 The knowledge of human immunology has improved exponentially in recent years, and more advances in the near future are certainly imminent. The immune system is extremely …See details»
Partnering with UBC on Canada’s Immuno ... - Health Research BC
Mar 15, 2023 As a provincial organization, our work extends across many Indigenous lands and territories throughout British Columbia. We acknowledge with respect and humility that our Vancouver offices are located on the traditional and unceded territories of the xʷməθkʷəy̓əm (Musqueam), Skwxwú7mesh (Squamish), and səl̓ilwətaɁɬ (Tsleil-Waututh) Nations.See details»
What companies do now will determine their future in the …
Dec 23, 2024 Organization-wide results demand more advanced AI technologies that cut across silos, such as enterprise-grade AI agents and the agentic process automation currently accelerating in availability and adoption. A South American energy company and early adopter of AI, for example, saw the technology’s potential to reshape internal processes and ...See details»
Breaking Through the Therapeutic Ceiling with First-In-Class ...
NSCLC: Non-Small Cell Lung Cancer; PDAC: Pancreatic Ductal AdenoCarcinoma; OC: Ovarian Cancer; ALL: Acute Lymphoblastic Leukemia.UC: Ulcerative Colitis.;IND: Investigational New …See details»
What’s next for an immuno-oncology powerhouse? - Nature
Aug 13, 2021 Dean Li, the recently appointed President of Merck Research Laboratories, discusses his immuno-oncology ambitions, emerging antiviral opportunities and the changing …See details»
Kenki Taniguchi - CEO @ ImmunoFuture - Crunchbase
Primary Organization . ImmunoFuture . Location Tokyo, Tokyo, Japan; Regions Asia-Pacific (APAC) Also Known As 谷口賢記; Kenki Taniguchi is the CEO of ImmunoFuture. Jobs. Edit …See details»